Results 241 to 250 of about 298,867 (391)

Toward Personalized Medicine in Type 1 Diabetes: Understanding How Patient Heterogeneity Influences Therapeutic Efficacy

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4529-4545, June 2026.
ABSTRACT Pharmacologic interventions for type 1 diabetes (T1D) have advanced significantly in recent years with the advent of the first FDA approved therapy teplizumab for delaying symptomatic disease onset in 2022. Despite this progress, major hurdles remain in moving toward personalized medicine approaches for T1D.
Jasmine Pipella, Peter J. Thompson
wiley   +1 more source

Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood: A Case Series. [PDF]

open access: yesPediatr Blood Cancer
Zarrabi M   +5 more
europepmc   +1 more source

Epidemiological evidence for the role of puberty and immune senescence in Hodgkin lymphoma aetiology from 1992 Danish cases

open access: yesInternational Journal of Cancer, Volume 158, Issue 10, Page 2629-2640, 15 May 2026.
What's New? The understanding of the epidemiological and clinical distinctions between Epstein–Barr virus (EBV)‐positive and EBV‐negative classic Hodgkin lymphoma remains incomplete. Here, the authors generated unique sets of population‐based sex‐ and age‐specific incidence rates of classic Hodgkin lymphoma in Denmark stratified by histological subtype
Klaus Rostgaard   +18 more
wiley   +1 more source

Detection of Diagnostic Antibodies in Immune‐Mediated Diseases: A Focus on Antigens and Technologies

open access: yesChemBioChem, Volume 27, Issue 9, 14 May 2026.
This review explores autoantibody detection in immune‐mediated diseases, highlighting autoantigens including post‐translational modifications. We compared enzyme‐linked immunosorbent assay and indirect immunofluorescence with automated chemiluminescence platforms.
Silvia Bracci   +5 more
wiley   +1 more source

Manufacturing and clinical applications of non‐CAR‐T immune effector cells

open access: yes
Transfusion, EarlyView.
Thane Kubik   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy